Close menu




January 8th, 2025 | 07:30 CET

Bayer, First Hydrogen, Volkswagen – Turnaround Candidates for 2025 Under Review

  • Hydrogen
  • Fuelcells
  • Electromobility
  • Pharma
Photo credits: pixabay.com

After the year-end portfolio window-dressing in December, the new year starts with the hunt for the right stocks for 2025. Special attention should be given to turnaround candidates, meaning stocks that underperformed last year. These companies have faced challenging times and have often already begun addressing their issues through strategic realignment. Sometimes, market conditions for a sector can improve significantly from one year to the next, and then the stocks of these companies often rise disproportionately. Identifying the right stocks requires thorough research. We look at three potential turnaround candidates.

time to read: 4 minutes | Author: Armin Schulz
ISIN: BAYER AG NA O.N. | DE000BAY0017 , First Hydrogen Corp. | CA32057N1042 , VOLKSWAGEN AG VZO O.N. | DE0007664039

Table of contents:


    Bayer – Plenty to do

    In 2024, Bayer was facing enormous challenges. A low sales growth of just 1% year-on-year and a decline in earnings per share to EUR 4 put the Company's difficulties in perspective. The performance of the agriculture business, which is traditionally considered a key revenue driver, was particularly negative, with revenue falling by 2% in the first 9 months and as much as 4% in the third quarter. The reasons for this were a series of unfavourable weather conditions, diseases such as corn stalk disease in Latin America, falling raw material prices, price competition, and price indexation. Glyphosate sales experienced a particularly sharp decline of 19%.

    Nevertheless, there are some bright spots. Ophthalmology remains a high-growth business, with the drug Eylea showing an 8.6% increase in sales. Furthermore, the new high-dose version Eylea HD has proven successful in a Phase 3 study, raising hopes for further growth. In Australia, Bayer was cleared in a judgment in the context of the Monsanto class action lawsuits, which should resolve all legal disputes. Of the last 22 cases, 15 have been won, and it seems possible to contain the litigation surrounding glyphosate in the United States.

    Nevertheless, Bayer will remain an uncertain candidate for 2025. Strong growth of new products such as Nubeqa and Kerendia, as well as stabilizing Eylea, provide opportunities, but the loss of sales from the expired Xarelto patent continues to weigh on the share. Investors will need to assess how the Company addresses competitive challenges and structural difficulties, particularly in the Crop Science division. If Bayer manages to manage costs better, consistently expand new business areas, and end the glyphosate litigation, the Company could stabilize in the long term. The share is currently trying to break through the EUR 20 mark and is trading at EUR 19.898.

    First Hydrogen – Hydrogen from modular nuclear reactors

    First Hydrogen's shares were also unable to escape the downward pull of the hydrogen division and fell by a good 75% last year. The Company, which specializes in green hydrogen solutions, was able to demonstrate some successes. The light hydrogen-powered commercial vehicle, manufactured using the best-of approach, received road approval and was put through its paces by a number of fleet operators. The feedback was very positive and the advantages over electric vehicles were clear. In order to offer customers everything from a single source, the Canadians worked on the 'Hydrogen-as-a-Service' concept, which, in addition to a refuelling station infrastructure, also includes the production of green hydrogen.

    In December, a company update was provided indicating that the production of green hydrogen using small modular nuclear reactors (SMRs) is being looked at more closely. These SMRs offer a cost-effective and low-carbon alternative to conventional energy sources and ensure a stable power supply, even in regions with limited grid access. With a cost of around USD 36 per MWh, or the equivalent of 3.6 US cents per kWh, SMRs are a competitive energy source for the production of hydrogen. France has long been promoting the use of nuclear power for the production of green hydrogen.

    In addition to the constant availability of SMRs, scalability, fast construction times, safety, and efficient land use are significant advantages. Installing SMRs for hydrogen production near petrol stations minimizes transport costs and allows excess electricity to be fed into local grids. This strategy facilitates the energy transition and opens up new sources of income. The low-priced hydrogen significantly improves economic efficiency and can finally lead to a breakthrough for the technology. Since September, the share price has been moving sideways between CAD 0.31 and CAD 0.44. It is currently available for CAD 0.375.

    Volkswagen – Fast charging network with XPeng

    2024 was a challenging year for Volkswagen, and it ended bitterly. The subsidiary Cariad, which has already been criticized for the poor software for its electric vehicles, had to announce a serious data breach. The Chaos Computer Club had brought this to the attention of the Wolfsburg-based company. The data of around 800,000 vehicles was freely accessible on Amazon cloud servers, and in some cases, even precise location data was available. CEO Oliver Blume emphasized in an interview that comprehensive reforms were necessary to solve the structural problems and lead Volkswagen into a better future.

    In my previous article on Volkswagen, I pointed out the favourable valuation of the share. Shortly afterwards, the collaboration with XPeng to establish a joint fast-charging network in China was announced. A total of 20,000 charging points are planned, offering a charging capacity of up to 800 kW. The modern charging infrastructure will help the Wolfsburg-based company to polish up its image in China. Experts view the partnership between the two parties as promising.

    Positive news came from the subsidiary Rivian, which delivered convincing results. Around 14,000 vehicles were delivered in the fourth quarter, exceeding analyst expectations and successfully resisting the challenging market environment. Rivian may become profitable as early as 2025, which could further boost its share price. For Volkswagen investors, the future dividend policy will be of particular interest. A cut seems to be a foregone conclusion, but the extent remains to be seen. After hitting a low of around EUR 80 in early September, the stock has recovered and is currently trading at EUR 89.76.


    Bayer continues to struggle with structural challenges, but new products like Nubeqa and a focus on ophthalmology offer long-term opportunities. First Hydrogen relies on innovative technologies, such as small modular nuclear reactors, to make hydrogen production more economical and offers an interesting alternative for fleet operators with its hydrogen-powered light commercial vehicles. Volkswagen is trying to gain a foothold in China through its partnership with XPeng. At the same time, the Wolfsburg-based company needs to get its software problems under control. On the positive side, the numbers from its Rivian subsidiary are promising, with the Company nearing profitability.


    Conflict of interest

    Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may hold shares or other financial instruments of the aforementioned companies in the future or may bet on rising or falling prices and thus a conflict of interest may arise in the future. The Relevant Persons reserve the right to buy or sell shares or other financial instruments of the Company at any time (hereinafter each a "Transaction"). Transactions may, under certain circumstances, influence the respective price of the shares or other financial instruments of the Company.

    In addition, Apaton Finance GmbH is active in the context of the preparation and publication of the reporting in paid contractual relationships.

    For this reason, there is a concrete conflict of interest.

    The above information on existing conflicts of interest applies to all types and forms of publication used by Apaton Finance GmbH for publications on companies.

    Risk notice

    Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and the like on news.financial. These contents are exclusively for the information of the readers and do not represent any call to action or recommendations, neither explicitly nor implicitly they are to be understood as an assurance of possible price developments. The contents do not replace individual expert investment advice and do not constitute an offer to sell the discussed share(s) or other financial instruments, nor an invitation to buy or sell such.

    The content is expressly not a financial analysis, but a journalistic or advertising text. Readers or users who make investment decisions or carry out transactions on the basis of the information provided here do so entirely at their own risk. No contractual relationship is established between Apaton Finance GmbH and its readers or the users of its offers, as our information only refers to the company and not to the investment decision of the reader or user.

    The acquisition of financial instruments involves high risks, which can lead to the total loss of the invested capital. The information published by Apaton Finance GmbH and its authors is based on careful research. Nevertheless, no liability is assumed for financial losses or a content-related guarantee for the topicality, correctness, appropriateness and completeness of the content provided here. Please also note our Terms of use.


    Der Autor

    Armin Schulz

    Born in Mönchengladbach, he studied business administration in the Netherlands. In the course of his studies he came into contact with the stock exchange for the first time. He has more than 25 years of experience in stock market business.

    About the author



    Related comments:

    Commented by Juliane Zielonka on March 13th, 2025 | 07:00 CET

    Big Pharma's billion-dollar markets under pressure – NetraMark as the key for Bayer and Novo Nordisk?

    • Healthcare
    • healthtech
    • Biotechnology
    • Pharma
    • AI
    • hightech

    In 2025, the pharmaceutical market faces significant challenges, including rising costs and regulatory hurdles. In this environment, companies like NetraMark, Bayer, and Novo Nordisk could make a significant difference through innovative solutions and strategic partnerships. NetraMark, a Canadian HealthTech company, is revolutionizing clinical trials with AI technology, which could be particularly beneficial in the areas of research into active ingredients for the central nervous system and in oncology. These are currently the biggest dropouts in industry. NetraMark's technology could increase the efficiency of drug development and open up new opportunities for investors. Bayer is focusing on targeted therapies in precision oncology and has a promising drug in development that specifically targets an overarching mutation in various cancers. Novo Nordisk is cementing its reputation as an innovator in the fight against chronic obesity, particularly with its successor to the obesity drug CagriSema. The Phase III REDEFINE 2 study achieved its primary objective, although the results fell short of high expectations. A closer look is now warranted.

    Read

    Commented by Armin Schulz on March 12th, 2025 | 07:00 CET

    Nel ASA, First Hydrogen, Volkswagen – The EU and Germany are pumping billions into hydrogen – who is cashing in?

    • Hydrogen
    • greenhydrogen
    • renewableenergies
    • Electromobility

    As the global search for alternatives to oil and gas gathers pace, hydrogen could become the secret star of the energy transition. Green hydrogen could become a game changer not only for factories but also in the transport sector. The EU has now launched a multi-billion funding program – in Austria alone, 112,000 tons of green hydrogen are to be produced with it, and in Lithuania, 13,000 tons. One thing is clear: from 2027, it will be noticeably more expensive at the gas station. Experts expect price jumps of between 38 cents and 1 euro per liter. Suddenly, many are looking again more closely at emission-free drives. Innovative companies are driving this technology forward and positioning themselves as pioneers of an emission-free era. Opportunities are opening up for investors. Those who invest in hydrogen players early on could benefit from the upheaval in the energy and automotive industries. But which companies are setting the trends?

    Read

    Commented by Stefan Feulner on March 11th, 2025 | 07:30 CET

    Bayer, BioNxt Solutions, Novo Nordisk – The pressure is on

    • Biotechnology
    • Biotech
    • Pharma

    The biotech sector has started the new year with momentum, and the acquisition wave is heating up, as confirmed by Johnson & Johnson's acquisition of Intra-Cellular Therapies for USD 15 billion. The trend will likely continue as major pharmaceutical companies are under massive pressure to strengthen their portfolios. After all, drug patents worth over USD 200 billion will expire by the end of the decade. This will force the giants to make strategic acquisitions.

    Read